Security key
M0740A108
Alpha Tau Medical Ltd. - Ordinary Shares, no par value (DRTS)
CUSIP: M0740A108
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Ordinary Shares, no par value
- Total 13F shares
- 2,413,239
- Total 13F value
- $11,944,991
- Share change
- +283,000
- SEC-reported price per share
- $4.95
- Number of holders
- 35
- Value change
- +$1,471,651
- Number of buys
- 12
- Number of sells
- 13
- Shares outstanding
- 86,723,804
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
35
Top holders
10
DRTS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Previous quarter: Q3 2025
Alpha Tau Medical Ltd. SEC filings
Alpha Tau Medical Ltd. company facts
Broader feeds
Reporting periods
Holder history for CUSIP M0740A108
Recent filing periods:
Ownership snapshot
Top reported holders of DRTS - Alpha Tau Medical Ltd. - Ordinary Shares, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORAMED PHARMACEUTICALS INC.
Disclosed value leader
Uzi Sofer
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G
13F
Lead comparable stake: 20%
13D/G row: ORAMED PHARMACEUTICALS INC.
Showing 1-6 of 15 holder rows.
Quick read
ORAMED PHARMACEUTICALS INC. leads the comparable SEC ownership view at 20%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORAMED PHARMACEUTICALS INC.'s linked filing trail.
Comparable ownership
Top 5
ORAMED PHARMACEUTICALS INC.
20%
Uzi Sofer
16%
HighTower Advisors, LLC
0.79%
LEVIN CAPITAL STRATEGIES, L.P.
0.24%
NorthCoast Asset Management LLC
0.23%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. |
13D/G
|
20%
|
$37,250,719
14,110,121 shares
|
$0 | 24 Apr 2025 |
| Uzi Sofer |
13D/G
|
16%
|
$42,751,366
13,702,361 shares
|
$0 | 31 Dec 2022 |
| HighTower Advisors, LLC |
13F
Company
|
0.79%
|
$3,096,359
686,554 shares
|
— | 30 Sep 2025 |
| LEVIN CAPITAL STRATEGIES, L.P. |
13F
Company
|
0.24%
|
$923,260
204,714 shares
|
— | 30 Sep 2025 |
| NorthCoast Asset Management LLC |
13F
Company
|
0.23%
|
$916,572
203,231 shares
|
— | 30 Sep 2025 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
0.07%
|
$279,169
61,900 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
35
Shares
2,413,239
Rows available
35
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
31
Q4 2025 holders
35
Holder diff
4
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend